Beta Thalassemia Clinical Trial
Official title:
Effects of Spirulina on Cardiac Functions in Children With Beta Thalassemia Major
The aim of this study is to evaluate the cardioprotective effect of spirulina in children with beta thalassemia.
The aim of this study is to evaluate the cardioprotective effect of spirulina in children
with beta thalassemia.
this study will be carried on thirty children with beta thalassemia major from those
attending the Hematology Unit of Pediatric department at Tanta University Hospital, and
another thirty healthy children of matched age and sex will be enrolled as controls.
all studied children will be subjected to careful history taking and through clinical
examination. laboratory investigations will be done including complete blood count,
hemoglobin electrophoresis, serum ferritin, liver and kidney functions, and troponin-1 plasma
level. echocardiographic assessment of the cardiac functions will be done for all patients.
Source data will be the patients medical records.
oral spirulina will be given for studied patients for 3 months, and clinical examination,
laboratory investigations and cardiac functions will be assessed at the time of inclusion in
the study, and again after 3 months of regular spirulina supplementation.
An informed consent will be obtained from parents of all included subjects. the results of
this study will be tabulated and statistically analyzed using Statistical Package for the
Social Sciences (SPSS).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01049854 -
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
|
Phase 2 | |
| Active, not recruiting |
NCT00408447 -
Stem Cell Transplant in Sickle Cell Disease and Thalassemia
|
Phase 2 | |
| Recruiting |
NCT06073860 -
A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia
|
||
| Recruiting |
NCT05357482 -
Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia
|
Phase 1/Phase 2 | |
| Completed |
NCT00790127 -
Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia
|
Phase 1/Phase 2 | |
| Completed |
NCT00005934 -
5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia
|
Phase 2 | |
| Completed |
NCT01931644 -
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
|
||
| Completed |
NCT00159042 -
Genetic Factors Affecting the Severity of Beta Thalassemia
|
N/A | |
| Recruiting |
NCT04929574 -
Evaluation of Heart Status in Patients of Beta Thalassemia Using Echocardiogram
|
||
| Recruiting |
NCT04918056 -
Genetic Variants Affecting the Clinical Severity of Beta Thalassemia
|
||
| Completed |
NCT00001958 -
Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia)
|
Phase 2 | |
| Recruiting |
NCT04917978 -
Association of Hb F Level With Clinical Severity of Beta Thalassemia
|